- Home
- CLRB vs JAGX Comparison
CLRB vs JAGX Comparison
Compare CLRB & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- JAGX
- Stock Information
- Founded
- CLRB 2002
- JAGX 2013
- Country
- CLRB United States
- JAGX United States
- Employees
- CLRB N/A
- JAGX N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- JAGX Health Care
- Exchange
- CLRB Nasdaq
- JAGX Nasdaq
- Market Cap
- CLRB 10.7M
- JAGX 11.3M
- IPO Year
- CLRB N/A
- JAGX N/A
- Fundamental
- Price
- CLRB $0.25
- JAGX $0.90
- Analyst Decision
- CLRB Buy
- JAGX
- Analyst Count
- CLRB 2
- JAGX 0
- Target Price
- CLRB $28.00
- JAGX N/A
- AVG Volume (30 Days)
- CLRB 3.8M
- JAGX 473.7K
- Earning Date
- CLRB 11-18-2024
- JAGX 11-13-2024
- Dividend Yield
- CLRB N/A
- JAGX N/A
- EPS Growth
- CLRB N/A
- JAGX N/A
- EPS
- CLRB N/A
- JAGX N/A
- Revenue
- CLRB N/A
- JAGX $10,480,000.00
- Revenue This Year
- CLRB N/A
- JAGX $32.33
- Revenue Next Year
- CLRB N/A
- JAGX $43.63
- P/E Ratio
- CLRB N/A
- JAGX N/A
- Revenue Growth
- CLRB N/A
- JAGX N/A
- 52 Week Low
- CLRB $0.23
- JAGX $0.84
- 52 Week High
- CLRB $4.45
- JAGX $21.60
- Technical
- Relative Strength Index (RSI)
- CLRB 6.45
- JAGX 44.80
- Support Level
- CLRB $0.23
- JAGX $0.84
- Resistance Level
- CLRB $0.28
- JAGX $1.29
- Average True Range (ATR)
- CLRB 0.07
- JAGX 0.09
- MACD
- CLRB -0.10
- JAGX -0.00
- Stochastic Oscillator
- CLRB 2.70
- JAGX 20.76
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.